Article Search
검색
검색 팝업 닫기

All Menu

Metrics

Help

  • 1. Aims and Scope

    Gut and Liver is an international journal of gastroenterology, focusing on the gastrointestinal tract, liver, biliary tree, pancreas, motility, and neurogastroenterology. Gut atnd Liver delivers up-to-date, authoritative papers on both clinical and research-based topics in gastroenterology. The Journal publishes original articles, case reports, brief communications, letters to the editor and invited review articles in the field of gastroenterology. The Journal is operated by internationally renowned editorial boards and designed to provide a global opportunity to promote academic developments in the field of gastroenterology and hepatology. +MORE

  • 2. Editorial Board

    Editor-in-Chief + MORE

    Editor-in-Chief
    Yong Chan Lee Professor of Medicine
    Director, Gastrointestinal Research Laboratory
    Veterans Affairs Medical Center, Univ. California San Francisco
    San Francisco, USA

    Deputy Editor

    Deputy Editor
    Jong Pil Im Seoul National University College of Medicine, Seoul, Korea
    Robert S. Bresalier University of Texas M. D. Anderson Cancer Center, Houston, USA
    Steven H. Itzkowitz Mount Sinai Medical Center, NY, USA
  • 3. Editorial Office
    + MORE
  • 4. Articles
  • 5. Instructions for Authors
  • 6. File Download (PDF version)
  • 7. Ethical Standards
  • 8. Peer Review

    All papers submitted to Gut and Liver are reviewed by the editorial team before being sent out for an external peer review to rule out papers that have low priority, insufficient originality, scientific flaws, or the absence of a message of importance to the readers of the Journal. A decision about these papers will usually be made within two or three weeks.
    The remaining articles are usually sent to two reviewers. It would be very helpful if you could suggest a selection of reviewers and include their contact details. We may not always use the reviewers you recommend, but suggesting reviewers will make our reviewer database much richer; in the end, everyone will benefit. We reserve the right to return manuscripts in which no reviewers are suggested.

    The final responsibility for the decision to accept or reject lies with the editors. In many cases, papers may be rejected despite favorable reviews because of editorial policy or a lack of space. The editor retains the right to determine publication priorities, the style of the paper, and to request, if necessary, that the material submitted be shortened for publication.

Search

Search

Year

to

Article Type

Original Article

Split Viewer

Helicobacter pylori Infection Enhances Gastric Mucosal Inflammation in Individuals Carrying the 260-T Allele of the CD14 Gene

Eun Jung Kim*, Woo Chul Chung**, Kang-Moon Lee*, Chang Nyol Paik*, Sang Bae Kim*, You Suk Oh*, Yang Woon Lee*, Sung-Goo Kang†, and Seung June Noh‡

Author Info +

*Department of Internal Medicine, St. Vincent's Hospital, The Catholic University of Korea College of Medicine, Suwon, Korea.

†Department of Family Medicine, St. Vincent's Hospital, The Catholic University of Korea College of Medicine, Suwon, Korea.

‡The Research Institute, St. Vincent's Hospital, The Catholic University of Korea College of Medicine, Suwon, Korea.

Correspondence to: Woo Chul Chung. Department of Internal Medicine, St. Vincent's Hospital, The Catholic University of Korea College of Medicine, 93 Jungbu-daero, Paldal-gu, Suwon 442-723, Korea. Tel: +82-31-249-7137, Fax: +82-31-253-8898, jwchulkr@catholic.ac.kr

Received: August 13, 2012; Revised: September 19, 2012; Accepted: October 5, 2012

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Gut Liver 2013;7(3):317-322. https://doi.org/10.5009/gnl.2013.7.3.317

Published online May 13, 2013, Published date May 31, 2013

Copyright © Gut and Liver.

Abstract

Go to

Background/Aims

We aim to evaluate the association between promoter polymorphism of the clusters of differentiation 14 (CD14) gene and Helicobacter pylori-induced gastric mucosal inflammation in a healthy Korean population.

Methods

The study population consisted of 267 healthy subjects who visited our hospital for free nationwide gastric cancer screening. Promoter polymorphism at -260 C/T of the CD14 gene was determined by polymerase chain reaction and restriction fragment length polymorphism analysis. The severity of gastric mucosal inflammation was estimated by a gastritis score based on the sum of the values of the grade and activity of the gastritis. Expression of soluble CD14 (sCD14) was assessed by quantitative sandwich ELISA.

Results

CD14 polymorphism was not associated with H. pylori infection. There were no significant differences in gastritis scores among the genotype subgroups, but subjects carrying the CD14 -260 CT/TT genotype had significantly higher sCD14 levels than those carrying the CC genotype. Subjects with the 260-T allele of the CD14 gene and H. pylori infection had significantly higher sCD14 levels than those with the same genotype but without infection.

Conclusions

In individuals with the T allele at the -260 site of the promoter region of the CD14 gene, H. pylori infection accentuates gastric mucosal inflammation.

Keywords: Helicobacter pylori, CD14, Genetic polymorphism, Gastritis

INTRODUCTION

Go to

Helicobacter pylori infection is strongly associated with the development of gastric cancer, particularly for intestinal type gastric cancer. With regard to the association between H. pylori induced gastritis and gastric cancer, it has been proposed that gastritis with severe mucosal damage may lead to the premalignant stage of atrophic gastritis/intestinal metaplasia, and subsequently the development of gastric cancer.1 Epidemiological evidence has accumulated that chronic inflammation of the gastric mucosa contributes to the pathogenesis of gastric cancer. The hyperproliferation of gastric epithelium caused by H. pylori infection is the starting point of a sequence of events that leads to gastric cancer.2 Moreover, immunogenetic factors play important roles in the progression and severity of gastric mucosal inflammation, thereby influencing the clinical outcome of H. pylori infection.

The clusters of differentiation 14 (CD14) are stimulated by lipopolysaccharide (LPS) generated by gram-negative bacteria.3 LPS binds to LPS-binding protein, and is transported to CD14 on the surfaces of monocytes.4,5H. pylori is a gram negative rod and LPS of H. pylori activates monocytes to express cytokines. This results in various cellular responses and inflammatory cell recruitment in H. pylori induced gastritis.6,7 There is single nucleotide polymorphism in the CD14 promoter sequence, located in the locus 5q23-31; this polymorphism involves a transition from cytosine (C) to thymine (T) in the position-260 from the translation starting site of the gene.8 This polymorphism is found near the recognition site for transcription factor Sp1 and seems to have a significant role in CD14 regulation.9 Recent studies have reported on the association between CD14 gene polymorphism and gastric cancer, but there have been no consistent results.10-12 The reason for the inconsistent results may be due to the heterogeneity of the races investigated, as gastric cancer is a multifactorial disease that results from a complex interaction of genetic and environmental factors.

Herein we focused on the acute and chronic inflammation of gastric mucosa in a healthy population without specific gastrointestinal disease and symptom. Furthermore, it is not known whether CD14 gene polymorphism is associated with H. pylori induced gastric inflammation in the Korean population. In this study, we aim to evaluate the association between CD14 promoter polymorphism and H. pylori infection. Also, we plan to elucidate the association between CD14 promotor polymorphism and gastric mucosal inflammation.

MATERIALS AND METHODS

Go to
1. Study population

Healthy adults were enrolled from St. Vincent's Hospital, The Catholic University of Korea College of Medicine from February 2009 to March 2010 and they visited the health care center for free nationwide gastric cancer screening in a Korean adult population. None of them had a history of H. pylori eradication or previous gastric surgery. They were asymptomatic examinees of regular health screening with a simple symptom questionnaire at the Health Promotion Center of the same hospital. This study was conducted on 267 healthy adults (169 males and 98 females) without hypertension, diabetes, cardiac disease, or any past history of chronic illness. Individuals with grossly severe gastric atrophy or ulceration, or who were taking specific gastrointestinal medication, nonsteroidal anti-inflammatory drugs, or any other drugs were excluded. Patients with conditions that might have substantial effects on our study results (e.g., serum creatinine >2.5 mg/dL, total bilirubin >3.0 mg/dL), or who were pregnant, had a psychiatric disorder or did not sign a consent form were also excluded. Alcohol drinking was defined as consumption of at least 20 g alcohol/day and up to 3 times per week. Smoking was defined as current smoker.

2. Specimen collection

Two biopsy specimens were taken during upper gastrointestinal endoscopy from greater curvature side of the midantrum and corpus for histology. About 2 mL of peripheral blood and 3 mL of serum samples were collected for analysis of CD14 polymorphism and sCD14 level.

3. Pathologic evaluation

During the endoscopic examinations, two biopsy specimens were taken from the antrum (the greater curvature of the midantrum) and the corpus (the greater curvature of the midbody) for histological assessment. The diagnosis of H. pylori infection was made by showing histologic evidence of H. pylori on a Warthin-Starry silver stain in any of two specimens from the antrum and corpus. A gastritis score was calculated by the summation of the grade and activity of the gastritis. The grading of gastritis was based on the degree of infiltration by lymphocytes and plasma cells. Gastritis activity was based on the degree of infiltration by neutrophilic granulocytes. Both values were scored using the updated Sydney system and scores ranged from 0 (none) to 3 (severe).13 Intestinal metaplasia was noted as absent, complete, or incomplete.

4. Polymorphism analysis

Genomic DNA was obtained from the peripheral blood lymphocytes of study subjects using the Genomic DNA Extraction Kit (Bioneer Corp., Daejeon, Korea). Genotypes of the CD14 promoter were determined by the polymerase chain reaction (PCR)-restriction fragment length polymorphism method. The CD14 promoter region containing -260C/T site was determined by using the PCR primer pairs 260 F5'-TGAGGATCATCCTTTTCCCAAAC-3'/260 R5'-CAGGCTTCACACTTGTGAACTCTTC-3'.

PCR reactions were set up using i-Star Taq DNA polymerase (iNtRON Biotechnology, Seoul, Korea). In a total reaction volume of 20 µL, 2 µL 10× buffer, 10 pmoL primer, 2 µL genomic DNA, and 2 µL dNTP mixture were combined. Reactions were run on Bio-Rad MyCycler thermal cyclers (BIO-RAD, Philadelphia, PA, USA). The PCR conditions were as follows: an initial denaturation at 95℃ for 5 minutes, followed by 35 cycles of denaturing at 94℃ for 30 seconds, annealing at 64℃ for 30 seconds, extension at 72℃ for 30 seconds and final incubation at 72℃ for 10 minutes and cooling to 4℃. The resultant PCR products (3 µL) were digested overnight at 37℃ with Hae III, the appropriate restriction enzyme (New England BioLabs, Beverly, MA, USA), and the digests were electrophoresed on 1.5% agarose gel. The CD14 C allele was cut into two fragments of 155 and 263 base pairs, whereas the T allele remained uncut, with a length of 418 base pairs (Fig. 1).

5. Estimation of sCD14 level

By a quantitative sandwich ELISA according to the manufacturer's recommendations (catalog no. DC140; R&D Systems Europe, Abdingdon, UK), the soluble CD14 (sCD14) level was determined.14 Samples (diluted 1:200) were added in duplicate to a microplate precoated with monoclonal anti-sCD14 antibodies, followed by incubation with, in succession, enzyme-linked polyclonal antibody specific for sCD14, substrate solution, and stop solution. Optical density was measured at 450 nm in a MRX Microplate Reader connected with Revelation Software (Dynateck Laboratories, Chantilly, VA, USA). A soluble CD14 standard (250 to 8,000 pg/mL) was included on each plate for standard curve production. A control sample was also included on each plate.

6. Statistics

Statistical analysis was conducted using IBM SPSS version 18.0 software (IBM, Armonk, NY, USA). Values were expressed as means±SD. Allele and genotype frequencies between the sexes were compared via chi-squared tests. The normality in the distributions was assessed using normal probability plots. Analysis of variance (ANOVA) or Student's t-test was used to assess normally distributed variables. Differences at the level of p<0.05 were regarded as statistically significant.

7. Ethics statement

Informed consent was obtained from all patients and the study was approved by the Institutional Review Board of The Catholic University of Korea College of Medicine (VC08TISI0082).

RESULTS

Go to
1. Basal characteristics of enrolled patients and CD14 polymorphism

Characteristics of the study population included in this study are presented in Table 1. The distributions of age and sex among subjects were not significantly different. For the CD14 -260 C/T allele, 144 heterozygotes (53.9%) and 123 homozygotes (46.1%) were identified and T allele frequency was 0.63. There were no differences between genotype subgroups; the frequencies of the CD14 -260 CC, -CT, and -TT genotypes were 10.4%, 53.9%, and 35.6%, respectively.

2. <italic>H. pylori</italic> status and gastritis score according to CD14 polymorphism

We next examined H. pylori infection and inflammatory activity of the gastric mucosa according to CD14 polymorphisms. The frequencies of the CC, CT, and TT genotypes were 10.4%, 53.9%, and 35.6%, respectively. There were no differences in age, sex, and the ratio of smokers and alcohol drinkers between the three genotypes. The frequencies of the CC, CT, and TT genotype with H. pylori infection were 71.4% (20/28), 48.6% (70/144), and 47.4% (45/95) and T allele frequency in subjects with H. pylori infection was 0.59. No association between CD14 genotypes and H. pylori infection status or intestinal metaplasia was found.

Inflammation of the gastric mucosa was expressed by the gastritis score described above. It was calculated by the summation of the grading and activity of gastritis based on the pathologic data. The gastritis scores for each genotype were 4.31±1.59, 3.93±2.22, and 4.00±2.40 in CC, CT, and TT genotype subgroups, respectively, and no relevant associations were observed. Among subjects with H. pylori infection, the gastritis scores were 4.95±1.19, 5.31±2.10, and 5.26±2.19 in subjects with CC, CT, and TT genotype, respectively, and there was also no statistical difference (p=0.47) (Table 1).

3. sCD14 level according to CD14 polymorphism

We also analyzed the relationships between CD14 genotypes, H. pylori infection and serum sCD14 levels. Although serum sCD14 levels (ng/mL) varied greatly among individuals, subjects carrying the CD14 -260 CT or TT genotype had significantly increased sCD14 levels compared with those carrying the CC genotype (p<0.01). The carriers of the T allele at the -260 site of the promoter region of the CD14 gene had the higher sCD14 levels than subjects with the non-T genotype (Fig. 2). Analyses with combined CD14 genotypes and H. pylori infection showed that subjects having the CD14 -260 CT or TT genotype with H. pylori infection had significantly higher sCD14 levels than those with the same genotype but without infection (Fig. 3).

DISCUSSION

Go to

In innate immunity, the germ line encoded pattern-recognition receptors play a central role in pathogen recognition and immune responses.15 CD14 is one of the pattern-recognition receptors and is an important mediator of the inflammatory response as the first line of host defense due to its ability to recognize LPS.16 Although H. pylori is minimally invasive and LPS of H. pylori has relatively low potency, it is important in CD14-mediated monocyte activation in gastric mucosal inflammation.6,7 CD14 exists in two forms: a membrane-bound form of CD14 anchored by glycosyl phosphatidylinositol, and a sCD14 without anchors, which is present in the plasma.3,5,16 In modulating LPS-induced apoptosis of endothelial cells, sCD14 may be an important molecule and is usually elevated in many chronic infectious and inflammatory conditions. As for gastric mucosal inflammation, LPS of H. pylori has the ability to bind CD14 and activate monocytes and induce an autoimmune response. It results in gastric mucosal injury, and consequently, the sCD14 level may be a marker of H. pylori induced gastric inflammation.17,18 It has been known that CD14 polymorphism is associated with circulating sCD14 levels and it modifies the environmental effect in many other disease conditions.19,20 However, there is a limited data on the functional effects of this polymorphism on gastric mucosal immunity and inflammation.

CD14 -260 polymorphism has been studied in various inflammatory conditions, including cardiovascular disease, infectious disease, chronic hepatitis, and inflammatory bowel disease, and it is known to be associated with enhanced inflammatory reaction.21-28 With regard to gastrointestinal conditions, individuals carrying the T-allele or TT genotype have an increased risk for ulcerative colitis and Crohn's disease.27,28 In this study, taking the gastritis score as a marker for gastric mucosal inflammation, we could not find an association between CD14 -260 polymorphism and gastritis score. Although the differences were not statistically significant, the subjects who had the T allele and H. pylori infection tended to have higher gastritis scores, compared with the CD14 -260 CC genotype. In this study, two pathologists independently reviewed for histological assessment. To some extent, subjective differences of interpretation between pathologists would exist and we measured sCD14 level as supplementary marker or objective evidence.

A previous study showed that increased concentrations of serum sCD14 have been found in H. pylori-infected patients and in patients with pronounced gastric inflammation.18 In this study, we found that the promoter polymorphism at -260 C/T of the CD14 gene had an effect on circulating sCD14 levels. Although none of the specific genotypes of CD14 polymorphism was susceptible to H. pylori infection, it was found that the T allele was associated with increased CD14 expression. Moreover, the subjects with the T allele had a much more prominent response to H. pylori. However, a limitation of this study was that we did not consider other risk factors, such as diet, age and duration of H. pylori infection. In our results, no significant difference of age was noted between the three groups. However, in post hoc analysis, mean age with CD14 -260 CT or TT genotype was significantly high than CC genotype (The data was not shown in the result.). By exclusion of macroscopically severe atrophy and intestinal metaplasia, age factor and duration of H. pylori infection would have little effect on gastric mucosal inflammation. Salt consumption is the single most important modifiable and preventable risk factor for gastric mucosal inflammation and gastric carcinogenesis. To overcome this limitation, a fairly large population study is necessitated.

As for CD14 polymorphism and gastric disease, it has been reported that there is no apparent association between this polymorphism and H. pylori-related gastric carcinoma in the Caucasian population, whereas this polymorphism was associated with a greater risk of H. pylori-related gastric carcinoma in the Han Chinese population.10,11 Our opposite results to those of the Caucasian population study may arise from the differences in the distribution of CD14 -260 C/T genotypes between the Korean and Caucasian populations, demonstrating the existence of ethnic genetic differences. There were very similar patterns in the distribution of CD14 -260 C/T genotypes between the Korean and Chinese populations, and the development of gastric cancer depends on ethnic-specific host susceptibility. However, in Japanese study, it was shown that the CD14 -159 TT and T carrier, considered as the high producing CD14 genotype, were associated with the reduced risk of intestinal type gastric cancer.29,30 Although the T allele seems to favor the inflammatory process, it was not associated with gastric cancer. As a reason for this inconsistent result, it is also possible that CD14 polymorphism is a risk factor only in the early stages of gastric mucosal inflammation, and is not involved in subsequent carcinogenic progression. In Japanese, it may confer protection against gastric mucosal atrophy caused by severe inflammation and thus may reduce the risk of intestinal type gastric cancer.30

The disease pattern is determined through the host immune responses affected by many other environmental factors. In view of this point, we provided new information regarding the association between the promoter polymorphism of the CD14 gene and H. pylori-induced gastric mucosal inflammation in healthy population without specific gastrointestinal symptom. To our knowledge, there were a few papers describing association of CD14 polymorphism with gastric inflammation in patients with gastric cancer but not in patients with just gastritis. In conclusion, CD14 polymorphism was associated with circulating sCD14 levels. Although CD14 polymorphism was not associated with H. pylori infection, there was a close relationship between promoter polymorphism of CD14 -260 C/T and H. pylori induced gastric mucosal inflammation in a Korean population. In individuals with T allele at the -260 site of the promoter region of the CD14 gene, H. pylori infection accentuates gastric mucosal inflammation.

Figures

Go to
Fig. 1.Digestion of polymerase chain reaction products yielded bands of 418 bp in TT homozygotes, 263 and 155 bp in CC homozygotes, and all three bands in heterozygotes.
Fig. 2.Soluble CD14 (sCD14) levels in different CD14 -260 C/T genotypes and in subjects with Helicobacter pylori infection.

*p<0.05.

Fig. 3.Soluble CD14 (sCD14) levels in each CD14 -260 C/T genotype with or without Helicobacter pylori infection.

*p<0.05.

Tables

Go to


Demographic Characteristics, Gastritis Score, and Soluble CD14 Levels for Each Genotype of the CD14 -260 C/T Polymorphism


Data are presented as number (%) or mean±SD.

H. pylori, Helicobacter pylori; sCD14, soluble CD14.

*Statistically significant.

Data are presented as number (%) or mean±SD.

H. pylori, Helicobacter pylori; sCD14, soluble CD14.

*Statistically significant.

References

Go to
  1. Correa, P, Haenszel, W, Cuello, C, Tannenbaum, S, Archer, M. A model for gastric cancer epidemiology. Lancet, 1975;2;58-60.
    Pubmed
  2. Uemura, N, Okamoto, S, Yamamoto, S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med, 2001;345;784-789.
    Pubmed
  3. Ziegler-Heitbrock, HW, Ulevitch, RJ. CD14: cell surface receptor and differentiation marker. Immunol Today, 1993;14;121-125.
    Pubmed
  4. Wright, SD, Ramos, RA, Tobias, PS, Ulevitch, RJ, Mathison, JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science, 1990;249;1431-1433.
    Pubmed
  5. Schumann, RR, Rietschel, ET, Loppnow, H. The role of CD14 and lipopolysaccharide-binding protein (LBP) in the activation of different cell types by endotoxin. Med Microbiol Immunol, 1994;183;279-297.
    Pubmed
  6. Kirkland, T, Viriyakosol, S, Perez-Perez, GI, Blaser, MJ. Helicobacter pylori lipopolysaccharide can activate 70Z/3 cells via CD14. Infect Immun, 1997;65;604-608.
    Pubmed
  7. Bliss, CM, Golenbock, DT, Keates, S, Linevsky, JK, Kelly, CP. Helicobacter pylori lipopolysaccharide binds to CD14 and stimulates release of interleukin-8, epithelial neutrophil-activating peptide 78, and monocyte chemotactic protein 1 by human monocytes. Infect Immun, 1998;66;5357-5363.
    Pubmed
  8. de Aguiar, BB, Girardi, I, Paskulin, DD, et al. CD14 expression in the first 24h of sepsis: effect of -260C>T CD14 SNP. Immunol Invest, 2008;37;752-769.
    Pubmed
  9. LeVan, TD, Bloom, JW, Bailey, TJ, et al. A common single nucleotide polymorphism in the CD14 promoter decreases the affinity of Sp protein binding and enhances transcriptional activity. J Immunol, 2001;167;5838-5844.
    Pubmed
  10. Zhao, D, Sun, T, Zhang, X, et al. Role of CD14 promoter polymorphisms in Helicobacter pylori infection: related gastric carcinoma. Clin Cancer Res, 2007;13;2362-2368.
    Pubmed
  11. Hold, GL, Rabkin, CS, Gammon, MD, et al. CD14-159C/T and TLR9-1237T/C polymorphisms are not associated with gastric cancer risk in Caucasian populations. Eur J Cancer Prev, 2009;18;117-119.
    Pubmed
  12. Wu, MS, Cheng, TY, Shun, CT, Lin, MT, Chen, LC, Lin, JT. Functional polymorphisms of CD14 and toll-like receptor 4 in Taiwanese Chinese with Helicobacter pylori-related gastric malignancies. Hepatogastroenterology, 2006;53;807-810.
    Pubmed
  13. Dixon, MF, Genta, RM, Yardley, JH, Correa, P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol, 1996;20;1161-1181.
    Pubmed
  14. Xu, ZW, Zhang, T, Song, CJ, et al. Application of sandwich ELISA for detecting tag fusion proteins in high throughput. Appl Microbiol Biotechnol, 2008;81;183-189.
    Pubmed
  15. Medzhitov, R, Janeway, C. Innate immunity. N Engl J Med, 2000;343;338-344.
    Pubmed
  16. Pugin, J, Heumann, ID, Tomasz, A, et al. CD14 is a pattern recognition receptor. Immunity, 1994;1;509-516.
    Pubmed
  17. Karhukorpi, J, Yan, Y, Niemela, S, et al. Effect of CD14 promoter polymorphism and H. pylori infection and its clinical outcomes on circulating CD14. Clin Exp Immunol, 2002;128;326-332.
    Pubmed
  18. Naito, Y, Ito, M, Watanabe, T, Suzuki, H. Biomarkers in patients with gastric inflammation: a systematic review. Digestion, 2005;72;164-180.
    Pubmed
  19. Baldini, M, Lohman, IC, Halonen, M, Erickson, RP, Holt, PG, Martinez, FD. A Polymorphism* in the 5' flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E. Am J Respir Cell Mol Biol, 1999;20;976-983.
    Pubmed
  20. Lin, J, Yao, YM, Yu, Y, et al. Effects of CD14-159 C/T polymorphism on CD14 expression and the balance between proinflammatory and anti-inflammatory cytokines in whole blood culture. Shock, 2007;28;148-153.
    Pubmed
  21. Zhang, HF, Zhong, BL, Zhu, WL, et al. CD14 C-260T gene polymorphism and ischemic heart disease susceptibility: a HuGE review and meta-analysis. Genet Med, 2009;11;403-408.
    Pubmed
  22. Risley, P, Jerrard-Dunne, P, Sitzer, M, Buehler, A, von Kegler, S, Markus, HS. Promoter polymorphism in the endotoxin receptor (CD14) is associated with increased carotid atherosclerosis only in smokers: the Carotid Atherosclerosis Progression Study (CAPS). Stroke, 2003;34;600-604.
    Pubmed
  23. Raunio, T, Knuuttila, M, Karttunen, R, Vainio, O, Tervonen, T. Serum sCD14, polymorphism of CD14(-260) and periodontal infection. Oral Dis, 2009;15;484-489.
    Pubmed
  24. Heesen, M, Bloemeke, B, Schade, U, Obertacke, U, Majetschak, M. The -260 C→T promoter polymorphism of the lipopolysaccharide receptor CD14 and severe sepsis in trauma patients. Intensive Care Med, 2002;28;1161-1163.
    Pubmed
  25. Eng, HL, Chen, CH, Kuo, CC, Wu, JS, Wang, CH, Lin, TM. Association of CD14 promoter gene polymorphism and Chlamydia pneumoniae infection. J Infect Dis, 2003;188;90-97.
    Pubmed
  26. Yan, CG, Ren, GY, Wang, F, Zhu, DF, Zhuang, Y. CD14-159 and -260 gene polymorphisms are associated with HBV-related cirrhotic injury in Chinese Han patients. Chin J Physiol, 2008;51;94-99.
    Pubmed
  27. Baumgart, DC, Buning, C, Geerdts, L, et al. The c.1-260C>T promoter variant of CD14 but not the c.896A>G (p.D299G) variant of toll-like receptor 4 (TLR4) genes is associated with inflammatory bowel disease. Digestion, 2007;76;196-202.
    Pubmed
  28. Kim, EJ, Chung, WC, Lee, KM, et al. Association between toll-like receptors/CD14 gene polymorphisms and inflammatory bowel disease in Korean population. J Korean Med Sci, 2012;27;72-77.
    Pubmed
  29. Tahara, T, Shibata, T, Hirata, I, Nakano, H, Arisawa, T. CD14 promoter-159 polymorphism is associated with reduced risk of intestinal-type gastric cancer in a Japanese population. Dig Dis Sci, 2009;54;1508-1512.
    Pubmed
  30. Tahara, T, Arisawa, T, Shibata, T, Hirata, I, Nakano, H. Association of polymorphism of TLR4 and CD14 genes with gastroduodenal diseases in Japan. Inflammopharmacology, 2007;15;124-128.
    Pubmed

Article

Original Article

Gut Liver 2013; 7(3): 317-322

Published online May 31, 2013 https://doi.org/10.5009/gnl.2013.7.3.317

Copyright © Gut and Liver.

Helicobacter pylori Infection Enhances Gastric Mucosal Inflammation in Individuals Carrying the 260-T Allele of the CD14 Gene

Eun Jung Kim*, Woo Chul Chung**, Kang-Moon Lee*, Chang Nyol Paik*, Sang Bae Kim*, You Suk Oh*, Yang Woon Lee*, Sung-Goo Kang†, and Seung June Noh‡

*Department of Internal Medicine, St. Vincent's Hospital, The Catholic University of Korea College of Medicine, Suwon, Korea.

†Department of Family Medicine, St. Vincent's Hospital, The Catholic University of Korea College of Medicine, Suwon, Korea.

‡The Research Institute, St. Vincent's Hospital, The Catholic University of Korea College of Medicine, Suwon, Korea.

Correspondence to: Woo Chul Chung. Department of Internal Medicine, St. Vincent's Hospital, The Catholic University of Korea College of Medicine, 93 Jungbu-daero, Paldal-gu, Suwon 442-723, Korea. Tel: +82-31-249-7137, Fax: +82-31-253-8898, jwchulkr@catholic.ac.kr

Received: August 13, 2012; Revised: September 19, 2012; Accepted: October 5, 2012

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background/Aims

We aim to evaluate the association between promoter polymorphism of the clusters of differentiation 14 (CD14) gene and Helicobacter pylori-induced gastric mucosal inflammation in a healthy Korean population.

Methods

The study population consisted of 267 healthy subjects who visited our hospital for free nationwide gastric cancer screening. Promoter polymorphism at -260 C/T of the CD14 gene was determined by polymerase chain reaction and restriction fragment length polymorphism analysis. The severity of gastric mucosal inflammation was estimated by a gastritis score based on the sum of the values of the grade and activity of the gastritis. Expression of soluble CD14 (sCD14) was assessed by quantitative sandwich ELISA.

Results

CD14 polymorphism was not associated with H. pylori infection. There were no significant differences in gastritis scores among the genotype subgroups, but subjects carrying the CD14 -260 CT/TT genotype had significantly higher sCD14 levels than those carrying the CC genotype. Subjects with the 260-T allele of the CD14 gene and H. pylori infection had significantly higher sCD14 levels than those with the same genotype but without infection.

Conclusions

In individuals with the T allele at the -260 site of the promoter region of the CD14 gene, H. pylori infection accentuates gastric mucosal inflammation.

Keywords: Helicobacter pylori, CD14, Genetic polymorphism, Gastritis

INTRODUCTION

Helicobacter pylori infection is strongly associated with the development of gastric cancer, particularly for intestinal type gastric cancer. With regard to the association between H. pylori induced gastritis and gastric cancer, it has been proposed that gastritis with severe mucosal damage may lead to the premalignant stage of atrophic gastritis/intestinal metaplasia, and subsequently the development of gastric cancer.1 Epidemiological evidence has accumulated that chronic inflammation of the gastric mucosa contributes to the pathogenesis of gastric cancer. The hyperproliferation of gastric epithelium caused by H. pylori infection is the starting point of a sequence of events that leads to gastric cancer.2 Moreover, immunogenetic factors play important roles in the progression and severity of gastric mucosal inflammation, thereby influencing the clinical outcome of H. pylori infection.

The clusters of differentiation 14 (CD14) are stimulated by lipopolysaccharide (LPS) generated by gram-negative bacteria.3 LPS binds to LPS-binding protein, and is transported to CD14 on the surfaces of monocytes.4,5H. pylori is a gram negative rod and LPS of H. pylori activates monocytes to express cytokines. This results in various cellular responses and inflammatory cell recruitment in H. pylori induced gastritis.6,7 There is single nucleotide polymorphism in the CD14 promoter sequence, located in the locus 5q23-31; this polymorphism involves a transition from cytosine (C) to thymine (T) in the position-260 from the translation starting site of the gene.8 This polymorphism is found near the recognition site for transcription factor Sp1 and seems to have a significant role in CD14 regulation.9 Recent studies have reported on the association between CD14 gene polymorphism and gastric cancer, but there have been no consistent results.10-12 The reason for the inconsistent results may be due to the heterogeneity of the races investigated, as gastric cancer is a multifactorial disease that results from a complex interaction of genetic and environmental factors.

Herein we focused on the acute and chronic inflammation of gastric mucosa in a healthy population without specific gastrointestinal disease and symptom. Furthermore, it is not known whether CD14 gene polymorphism is associated with H. pylori induced gastric inflammation in the Korean population. In this study, we aim to evaluate the association between CD14 promoter polymorphism and H. pylori infection. Also, we plan to elucidate the association between CD14 promotor polymorphism and gastric mucosal inflammation.

MATERIALS AND METHODS

1. Study population

Healthy adults were enrolled from St. Vincent's Hospital, The Catholic University of Korea College of Medicine from February 2009 to March 2010 and they visited the health care center for free nationwide gastric cancer screening in a Korean adult population. None of them had a history of H. pylori eradication or previous gastric surgery. They were asymptomatic examinees of regular health screening with a simple symptom questionnaire at the Health Promotion Center of the same hospital. This study was conducted on 267 healthy adults (169 males and 98 females) without hypertension, diabetes, cardiac disease, or any past history of chronic illness. Individuals with grossly severe gastric atrophy or ulceration, or who were taking specific gastrointestinal medication, nonsteroidal anti-inflammatory drugs, or any other drugs were excluded. Patients with conditions that might have substantial effects on our study results (e.g., serum creatinine >2.5 mg/dL, total bilirubin >3.0 mg/dL), or who were pregnant, had a psychiatric disorder or did not sign a consent form were also excluded. Alcohol drinking was defined as consumption of at least 20 g alcohol/day and up to 3 times per week. Smoking was defined as current smoker.

2. Specimen collection

Two biopsy specimens were taken during upper gastrointestinal endoscopy from greater curvature side of the midantrum and corpus for histology. About 2 mL of peripheral blood and 3 mL of serum samples were collected for analysis of CD14 polymorphism and sCD14 level.

3. Pathologic evaluation

During the endoscopic examinations, two biopsy specimens were taken from the antrum (the greater curvature of the midantrum) and the corpus (the greater curvature of the midbody) for histological assessment. The diagnosis of H. pylori infection was made by showing histologic evidence of H. pylori on a Warthin-Starry silver stain in any of two specimens from the antrum and corpus. A gastritis score was calculated by the summation of the grade and activity of the gastritis. The grading of gastritis was based on the degree of infiltration by lymphocytes and plasma cells. Gastritis activity was based on the degree of infiltration by neutrophilic granulocytes. Both values were scored using the updated Sydney system and scores ranged from 0 (none) to 3 (severe).13 Intestinal metaplasia was noted as absent, complete, or incomplete.

4. Polymorphism analysis

Genomic DNA was obtained from the peripheral blood lymphocytes of study subjects using the Genomic DNA Extraction Kit (Bioneer Corp., Daejeon, Korea). Genotypes of the CD14 promoter were determined by the polymerase chain reaction (PCR)-restriction fragment length polymorphism method. The CD14 promoter region containing -260C/T site was determined by using the PCR primer pairs 260 F5'-TGAGGATCATCCTTTTCCCAAAC-3'/260 R5'-CAGGCTTCACACTTGTGAACTCTTC-3'.

PCR reactions were set up using i-Star Taq DNA polymerase (iNtRON Biotechnology, Seoul, Korea). In a total reaction volume of 20 µL, 2 µL 10× buffer, 10 pmoL primer, 2 µL genomic DNA, and 2 µL dNTP mixture were combined. Reactions were run on Bio-Rad MyCycler thermal cyclers (BIO-RAD, Philadelphia, PA, USA). The PCR conditions were as follows: an initial denaturation at 95℃ for 5 minutes, followed by 35 cycles of denaturing at 94℃ for 30 seconds, annealing at 64℃ for 30 seconds, extension at 72℃ for 30 seconds and final incubation at 72℃ for 10 minutes and cooling to 4℃. The resultant PCR products (3 µL) were digested overnight at 37℃ with Hae III, the appropriate restriction enzyme (New England BioLabs, Beverly, MA, USA), and the digests were electrophoresed on 1.5% agarose gel. The CD14 C allele was cut into two fragments of 155 and 263 base pairs, whereas the T allele remained uncut, with a length of 418 base pairs (Fig. 1).

5. Estimation of sCD14 level

By a quantitative sandwich ELISA according to the manufacturer's recommendations (catalog no. DC140; R&D Systems Europe, Abdingdon, UK), the soluble CD14 (sCD14) level was determined.14 Samples (diluted 1:200) were added in duplicate to a microplate precoated with monoclonal anti-sCD14 antibodies, followed by incubation with, in succession, enzyme-linked polyclonal antibody specific for sCD14, substrate solution, and stop solution. Optical density was measured at 450 nm in a MRX Microplate Reader connected with Revelation Software (Dynateck Laboratories, Chantilly, VA, USA). A soluble CD14 standard (250 to 8,000 pg/mL) was included on each plate for standard curve production. A control sample was also included on each plate.

6. Statistics

Statistical analysis was conducted using IBM SPSS version 18.0 software (IBM, Armonk, NY, USA). Values were expressed as means±SD. Allele and genotype frequencies between the sexes were compared via chi-squared tests. The normality in the distributions was assessed using normal probability plots. Analysis of variance (ANOVA) or Student's t-test was used to assess normally distributed variables. Differences at the level of p<0.05 were regarded as statistically significant.

7. Ethics statement

Informed consent was obtained from all patients and the study was approved by the Institutional Review Board of The Catholic University of Korea College of Medicine (VC08TISI0082).

RESULTS

1. Basal characteristics of enrolled patients and CD14 polymorphism

Characteristics of the study population included in this study are presented in Table 1. The distributions of age and sex among subjects were not significantly different. For the CD14 -260 C/T allele, 144 heterozygotes (53.9%) and 123 homozygotes (46.1%) were identified and T allele frequency was 0.63. There were no differences between genotype subgroups; the frequencies of the CD14 -260 CC, -CT, and -TT genotypes were 10.4%, 53.9%, and 35.6%, respectively.

2. <italic>H. pylori</italic> status and gastritis score according to CD14 polymorphism

We next examined H. pylori infection and inflammatory activity of the gastric mucosa according to CD14 polymorphisms. The frequencies of the CC, CT, and TT genotypes were 10.4%, 53.9%, and 35.6%, respectively. There were no differences in age, sex, and the ratio of smokers and alcohol drinkers between the three genotypes. The frequencies of the CC, CT, and TT genotype with H. pylori infection were 71.4% (20/28), 48.6% (70/144), and 47.4% (45/95) and T allele frequency in subjects with H. pylori infection was 0.59. No association between CD14 genotypes and H. pylori infection status or intestinal metaplasia was found.

Inflammation of the gastric mucosa was expressed by the gastritis score described above. It was calculated by the summation of the grading and activity of gastritis based on the pathologic data. The gastritis scores for each genotype were 4.31±1.59, 3.93±2.22, and 4.00±2.40 in CC, CT, and TT genotype subgroups, respectively, and no relevant associations were observed. Among subjects with H. pylori infection, the gastritis scores were 4.95±1.19, 5.31±2.10, and 5.26±2.19 in subjects with CC, CT, and TT genotype, respectively, and there was also no statistical difference (p=0.47) (Table 1).

3. sCD14 level according to CD14 polymorphism

We also analyzed the relationships between CD14 genotypes, H. pylori infection and serum sCD14 levels. Although serum sCD14 levels (ng/mL) varied greatly among individuals, subjects carrying the CD14 -260 CT or TT genotype had significantly increased sCD14 levels compared with those carrying the CC genotype (p<0.01). The carriers of the T allele at the -260 site of the promoter region of the CD14 gene had the higher sCD14 levels than subjects with the non-T genotype (Fig. 2). Analyses with combined CD14 genotypes and H. pylori infection showed that subjects having the CD14 -260 CT or TT genotype with H. pylori infection had significantly higher sCD14 levels than those with the same genotype but without infection (Fig. 3).

DISCUSSION

In innate immunity, the germ line encoded pattern-recognition receptors play a central role in pathogen recognition and immune responses.15 CD14 is one of the pattern-recognition receptors and is an important mediator of the inflammatory response as the first line of host defense due to its ability to recognize LPS.16 Although H. pylori is minimally invasive and LPS of H. pylori has relatively low potency, it is important in CD14-mediated monocyte activation in gastric mucosal inflammation.6,7 CD14 exists in two forms: a membrane-bound form of CD14 anchored by glycosyl phosphatidylinositol, and a sCD14 without anchors, which is present in the plasma.3,5,16 In modulating LPS-induced apoptosis of endothelial cells, sCD14 may be an important molecule and is usually elevated in many chronic infectious and inflammatory conditions. As for gastric mucosal inflammation, LPS of H. pylori has the ability to bind CD14 and activate monocytes and induce an autoimmune response. It results in gastric mucosal injury, and consequently, the sCD14 level may be a marker of H. pylori induced gastric inflammation.17,18 It has been known that CD14 polymorphism is associated with circulating sCD14 levels and it modifies the environmental effect in many other disease conditions.19,20 However, there is a limited data on the functional effects of this polymorphism on gastric mucosal immunity and inflammation.

CD14 -260 polymorphism has been studied in various inflammatory conditions, including cardiovascular disease, infectious disease, chronic hepatitis, and inflammatory bowel disease, and it is known to be associated with enhanced inflammatory reaction.21-28 With regard to gastrointestinal conditions, individuals carrying the T-allele or TT genotype have an increased risk for ulcerative colitis and Crohn's disease.27,28 In this study, taking the gastritis score as a marker for gastric mucosal inflammation, we could not find an association between CD14 -260 polymorphism and gastritis score. Although the differences were not statistically significant, the subjects who had the T allele and H. pylori infection tended to have higher gastritis scores, compared with the CD14 -260 CC genotype. In this study, two pathologists independently reviewed for histological assessment. To some extent, subjective differences of interpretation between pathologists would exist and we measured sCD14 level as supplementary marker or objective evidence.

A previous study showed that increased concentrations of serum sCD14 have been found in H. pylori-infected patients and in patients with pronounced gastric inflammation.18 In this study, we found that the promoter polymorphism at -260 C/T of the CD14 gene had an effect on circulating sCD14 levels. Although none of the specific genotypes of CD14 polymorphism was susceptible to H. pylori infection, it was found that the T allele was associated with increased CD14 expression. Moreover, the subjects with the T allele had a much more prominent response to H. pylori. However, a limitation of this study was that we did not consider other risk factors, such as diet, age and duration of H. pylori infection. In our results, no significant difference of age was noted between the three groups. However, in post hoc analysis, mean age with CD14 -260 CT or TT genotype was significantly high than CC genotype (The data was not shown in the result.). By exclusion of macroscopically severe atrophy and intestinal metaplasia, age factor and duration of H. pylori infection would have little effect on gastric mucosal inflammation. Salt consumption is the single most important modifiable and preventable risk factor for gastric mucosal inflammation and gastric carcinogenesis. To overcome this limitation, a fairly large population study is necessitated.

As for CD14 polymorphism and gastric disease, it has been reported that there is no apparent association between this polymorphism and H. pylori-related gastric carcinoma in the Caucasian population, whereas this polymorphism was associated with a greater risk of H. pylori-related gastric carcinoma in the Han Chinese population.10,11 Our opposite results to those of the Caucasian population study may arise from the differences in the distribution of CD14 -260 C/T genotypes between the Korean and Caucasian populations, demonstrating the existence of ethnic genetic differences. There were very similar patterns in the distribution of CD14 -260 C/T genotypes between the Korean and Chinese populations, and the development of gastric cancer depends on ethnic-specific host susceptibility. However, in Japanese study, it was shown that the CD14 -159 TT and T carrier, considered as the high producing CD14 genotype, were associated with the reduced risk of intestinal type gastric cancer.29,30 Although the T allele seems to favor the inflammatory process, it was not associated with gastric cancer. As a reason for this inconsistent result, it is also possible that CD14 polymorphism is a risk factor only in the early stages of gastric mucosal inflammation, and is not involved in subsequent carcinogenic progression. In Japanese, it may confer protection against gastric mucosal atrophy caused by severe inflammation and thus may reduce the risk of intestinal type gastric cancer.30

The disease pattern is determined through the host immune responses affected by many other environmental factors. In view of this point, we provided new information regarding the association between the promoter polymorphism of the CD14 gene and H. pylori-induced gastric mucosal inflammation in healthy population without specific gastrointestinal symptom. To our knowledge, there were a few papers describing association of CD14 polymorphism with gastric inflammation in patients with gastric cancer but not in patients with just gastritis. In conclusion, CD14 polymorphism was associated with circulating sCD14 levels. Although CD14 polymorphism was not associated with H. pylori infection, there was a close relationship between promoter polymorphism of CD14 -260 C/T and H. pylori induced gastric mucosal inflammation in a Korean population. In individuals with T allele at the -260 site of the promoter region of the CD14 gene, H. pylori infection accentuates gastric mucosal inflammation.

Fig 1.

Download
Figure 1.Digestion of polymerase chain reaction products yielded bands of 418 bp in TT homozygotes, 263 and 155 bp in CC homozygotes, and all three bands in heterozygotes.
Gut and Liver 2013; 7: 317-322https://doi.org/10.5009/gnl.2013.7.3.317

Fig 2.

Download
Figure 2.Soluble CD14 (sCD14) levels in different CD14 -260 C/T genotypes and in subjects with Helicobacter pylori infection.

*p<0.05.

Gut and Liver 2013; 7: 317-322https://doi.org/10.5009/gnl.2013.7.3.317

Fig 3.

Download
Figure 3.Soluble CD14 (sCD14) levels in each CD14 -260 C/T genotype with or without Helicobacter pylori infection.

*p<0.05.

Gut and Liver 2013; 7: 317-322https://doi.org/10.5009/gnl.2013.7.3.317

Table 1 Demographic Characteristics, Gastritis Score, and Soluble CD14 Levels for Each Genotype of the CD14 -260 C/T Polymorphism

Data are presented as number (%) or mean±SD.

H. pylori, Helicobacter pylori; sCD14, soluble CD14.

*Statistically significant.

|@|Data are presented as number (%) or mean±SD.

H. pylori, Helicobacter pylori; sCD14, soluble CD14.

*Statistically significant.

References

  1. Correa, P, Haenszel, W, Cuello, C, Tannenbaum, S, Archer, M. A model for gastric cancer epidemiology. Lancet, 1975;2;58-60.
    Pubmed
  2. Uemura, N, Okamoto, S, Yamamoto, S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med, 2001;345;784-789.
    Pubmed
  3. Ziegler-Heitbrock, HW, Ulevitch, RJ. CD14: cell surface receptor and differentiation marker. Immunol Today, 1993;14;121-125.
    Pubmed
  4. Wright, SD, Ramos, RA, Tobias, PS, Ulevitch, RJ, Mathison, JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science, 1990;249;1431-1433.
    Pubmed
  5. Schumann, RR, Rietschel, ET, Loppnow, H. The role of CD14 and lipopolysaccharide-binding protein (LBP) in the activation of different cell types by endotoxin. Med Microbiol Immunol, 1994;183;279-297.
    Pubmed
  6. Kirkland, T, Viriyakosol, S, Perez-Perez, GI, Blaser, MJ. Helicobacter pylori lipopolysaccharide can activate 70Z/3 cells via CD14. Infect Immun, 1997;65;604-608.
    Pubmed
  7. Bliss, CM, Golenbock, DT, Keates, S, Linevsky, JK, Kelly, CP. Helicobacter pylori lipopolysaccharide binds to CD14 and stimulates release of interleukin-8, epithelial neutrophil-activating peptide 78, and monocyte chemotactic protein 1 by human monocytes. Infect Immun, 1998;66;5357-5363.
    Pubmed
  8. de Aguiar, BB, Girardi, I, Paskulin, DD, et al. CD14 expression in the first 24h of sepsis: effect of -260C>T CD14 SNP. Immunol Invest, 2008;37;752-769.
    Pubmed
  9. LeVan, TD, Bloom, JW, Bailey, TJ, et al. A common single nucleotide polymorphism in the CD14 promoter decreases the affinity of Sp protein binding and enhances transcriptional activity. J Immunol, 2001;167;5838-5844.
    Pubmed
  10. Zhao, D, Sun, T, Zhang, X, et al. Role of CD14 promoter polymorphisms in Helicobacter pylori infection: related gastric carcinoma. Clin Cancer Res, 2007;13;2362-2368.
    Pubmed
  11. Hold, GL, Rabkin, CS, Gammon, MD, et al. CD14-159C/T and TLR9-1237T/C polymorphisms are not associated with gastric cancer risk in Caucasian populations. Eur J Cancer Prev, 2009;18;117-119.
    Pubmed
  12. Wu, MS, Cheng, TY, Shun, CT, Lin, MT, Chen, LC, Lin, JT. Functional polymorphisms of CD14 and toll-like receptor 4 in Taiwanese Chinese with Helicobacter pylori-related gastric malignancies. Hepatogastroenterology, 2006;53;807-810.
    Pubmed
  13. Dixon, MF, Genta, RM, Yardley, JH, Correa, P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol, 1996;20;1161-1181.
    Pubmed
  14. Xu, ZW, Zhang, T, Song, CJ, et al. Application of sandwich ELISA for detecting tag fusion proteins in high throughput. Appl Microbiol Biotechnol, 2008;81;183-189.
    Pubmed
  15. Medzhitov, R, Janeway, C. Innate immunity. N Engl J Med, 2000;343;338-344.
    Pubmed
  16. Pugin, J, Heumann, ID, Tomasz, A, et al. CD14 is a pattern recognition receptor. Immunity, 1994;1;509-516.
    Pubmed
  17. Karhukorpi, J, Yan, Y, Niemela, S, et al. Effect of CD14 promoter polymorphism and H. pylori infection and its clinical outcomes on circulating CD14. Clin Exp Immunol, 2002;128;326-332.
    Pubmed
  18. Naito, Y, Ito, M, Watanabe, T, Suzuki, H. Biomarkers in patients with gastric inflammation: a systematic review. Digestion, 2005;72;164-180.
    Pubmed
  19. Baldini, M, Lohman, IC, Halonen, M, Erickson, RP, Holt, PG, Martinez, FD. A Polymorphism* in the 5' flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E. Am J Respir Cell Mol Biol, 1999;20;976-983.
    Pubmed
  20. Lin, J, Yao, YM, Yu, Y, et al. Effects of CD14-159 C/T polymorphism on CD14 expression and the balance between proinflammatory and anti-inflammatory cytokines in whole blood culture. Shock, 2007;28;148-153.
    Pubmed
  21. Zhang, HF, Zhong, BL, Zhu, WL, et al. CD14 C-260T gene polymorphism and ischemic heart disease susceptibility: a HuGE review and meta-analysis. Genet Med, 2009;11;403-408.
    Pubmed
  22. Risley, P, Jerrard-Dunne, P, Sitzer, M, Buehler, A, von Kegler, S, Markus, HS. Promoter polymorphism in the endotoxin receptor (CD14) is associated with increased carotid atherosclerosis only in smokers: the Carotid Atherosclerosis Progression Study (CAPS). Stroke, 2003;34;600-604.
    Pubmed
  23. Raunio, T, Knuuttila, M, Karttunen, R, Vainio, O, Tervonen, T. Serum sCD14, polymorphism of CD14(-260) and periodontal infection. Oral Dis, 2009;15;484-489.
    Pubmed
  24. Heesen, M, Bloemeke, B, Schade, U, Obertacke, U, Majetschak, M. The -260 C→T promoter polymorphism of the lipopolysaccharide receptor CD14 and severe sepsis in trauma patients. Intensive Care Med, 2002;28;1161-1163.
    Pubmed
  25. Eng, HL, Chen, CH, Kuo, CC, Wu, JS, Wang, CH, Lin, TM. Association of CD14 promoter gene polymorphism and Chlamydia pneumoniae infection. J Infect Dis, 2003;188;90-97.
    Pubmed
  26. Yan, CG, Ren, GY, Wang, F, Zhu, DF, Zhuang, Y. CD14-159 and -260 gene polymorphisms are associated with HBV-related cirrhotic injury in Chinese Han patients. Chin J Physiol, 2008;51;94-99.
    Pubmed
  27. Baumgart, DC, Buning, C, Geerdts, L, et al. The c.1-260C>T promoter variant of CD14 but not the c.896A>G (p.D299G) variant of toll-like receptor 4 (TLR4) genes is associated with inflammatory bowel disease. Digestion, 2007;76;196-202.
    Pubmed
  28. Kim, EJ, Chung, WC, Lee, KM, et al. Association between toll-like receptors/CD14 gene polymorphisms and inflammatory bowel disease in Korean population. J Korean Med Sci, 2012;27;72-77.
    Pubmed
  29. Tahara, T, Shibata, T, Hirata, I, Nakano, H, Arisawa, T. CD14 promoter-159 polymorphism is associated with reduced risk of intestinal-type gastric cancer in a Japanese population. Dig Dis Sci, 2009;54;1508-1512.
    Pubmed
  30. Tahara, T, Arisawa, T, Shibata, T, Hirata, I, Nakano, H. Association of polymorphism of TLR4 and CD14 genes with gastroduodenal diseases in Japan. Inflammopharmacology, 2007;15;124-128.
    Pubmed
Gut and Liver

Vol.18 No.4
July, 2024

Frequency : Bimonthly

pISSN 1976-2283
eISSN 2005-1212

qrcode
qrcode

Share this article on :

  • line

Related articles in Gut and Liver

powered by TREND MD

Popular Keywords

Gut and LiverQR code Download
qr-code

Editorial Office